A new report predicts that the RSV (Respiratory Syncytial Virus) vaccine market will exceed $9 billion by 2029. As the RSV season is about to begin in September, pharmaceutical companies like Moderna and AstraZeneca are expected to enter the market with their respective vaccines – mRNA-1345 and Beyfortus. The report highlights the increasing demand for RSV vaccines due to the rising cases of respiratory infections, particularly in infants and older adults. The market is also driven by government initiatives to reduce the burden of RSV-related hospitalizations. With the potential for significant growth in the coming years, the RSV vaccine market is poised to offer lucrative opportunities for players in the pharmaceutical industry.
RSV Vaccine Market Expected to Surpass $9 Billion by 2029
Moderna's mRNA-1345 and AstraZeneca's Beyfortus are expected to compete in the RSV vaccine market as the RSV season approaches in September.
Latest from Blog
Doctors in the Upstate are conducting clinical trials on a cancer immunology vaccine that has the
A tiny fragment from the most dangerous asteroid in the solar system has arrived in the
Scientists have discovered a planet that is way too big for its tiny star. Its existence
No. 4 Florida State is aiming to win their 16th conference championship, taking on No. 14
Prince Harry and Meghan have been left off the guest list for the high society wedding
